Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 6,734Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 15Imbruvica

02 3Imbruvica

PharmaCompass

01

02

03

Brand Name : Imbruvica

arrow
Medlab Asia & Asia Health
Not Confirmed

Ibrutinib

Main Therapeutic Indication : Chronic lymphocytic leukemia

Currency : USD

2015 Revenue in Millions : 0

2014 Revenue in Millions : 754

Growth (%) : New Launch

Abbvie Company Banner

04

Brand Name : Imbruvica

arrow
Medlab Asia & Asia Health
Not Confirmed

Ibrutinib

Main Therapeutic Indication : Oncology

Currency : USD

2022 Revenue in Millions : 4,568

2021 Revenue in Millions : 5,408

Growth (%) : -16

Abbvie Company Banner

05

Brand Name : Imbruvica

arrow
Medlab Asia & Asia Health
Not Confirmed

Ibrutinib

Main Therapeutic Indication : Oncology

Currency : USD

2023 Revenue in Millions : 3,596

2022 Revenue in Millions : 4,568

Growth (%) : -21

Abbvie Company Banner

06

07

08

Brand Name : Imbruvica

arrow
Medlab Asia & Asia Health
Not Confirmed

Ibrutinib

Main Therapeutic Indication : Oncology

Currency : USD

2018 Revenue in Millions : 3,590

2017 Revenue in Millions : 2,573

Growth (%) : 40%

Abbvie Company Banner

09

10

Brand Name : Imbruvica

Ibrutinib

arrow
Medlab Asia & Asia Health
Not Confirmed

Brand Name : Imbruvica

arrow
Medlab Asia & Asia Health
Not Confirmed

Ibrutinib

Main Therapeutic Indication : Oncology

Currency : USD

2020 Revenue in Millions : 4,128

2019 Revenue in Millions : 3,411

Growth (%) : 21

blank